Back to Search Start Over

The US FDA authorises new oral treatment Mavenclad for multiple sclerosis

Source :
M2 Pharma. April 1, 2019
Publication Year :
2019

Abstract

M2 PHARMA-April 1, 2019-The US FDA authorises new oral treatment Mavenclad for multiple sclerosis (C)2019 M2 COMMUNICATIONS Public health agency the US Food and Drug Administration stated on Friday that [...]

Subjects

Subjects :
United States. Food and Drug Administration
Multiple sclerosis -- Drug therapy
Drug approval
Cladribine
Chemistry
Mavenclad (Medication)

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.580754796

Tools

Authors Abstract Subjects Details